Investment will accelerate go-to-market expansion and advance EAIGLE’s computer vision platform offerings for global supply chains.

BOSTON and ATLANTA, June 23, 2026 — EAIGLE, the leader in AI-Native gate and yard automation and data orchestration, today announced it has secured a growth funding round led by growth equity firm Noro-Moseley Partners, with participation from In Revenue Capital and Boreal Ventures. The investment will be used to accelerate go-to-market expansion and advance the development of EAIGLE’s proprietary automated logistics technology. Leading up to this round, EAIGLE achieved over 350% year-over-year revenue growth with Fortune 500 customers.

EAIGLE’s flagship product offering, Automated Vehicles Access Control (AVAC™) and YardSight™, leverages state-of-the-art computer vision to analyze camera feeds, instantly reading truck and trailer identifiers at the gate and across the yard, such as truck number, trailer number, logos, and numerous others. By automating real-time data capture, the AVAC™ and YardSight™ solutions eliminate labor-intensive, paper-based workflows and manual audits, and enable incoming drivers to navigate facilities seamlessly.

Transportation yards running EAIGLE’s solution on average benefit from decreasing dwell time at the gate to under 30 seconds, increasing gate throughput by 5x, significantly reducing theft & fraud events, along with detention fees, turnaround times, and operational bottlenecks – culminating in an ROI of 6 months or less, and annual savings of $500,000.

“EAIGLE’s AI technology is seeing rapid adoption among enterprise leaders across the retail, CPG, manufacturing, and transportation sectors,” said Vasant Kamath, General Partner at Noro-Moseley Partners. “Customers are finding incredible value in the market’s first truly automated facility management system, viewing it as a critical pillar in the digital transformation of their supply chains. EAIGLE seamlessly simplifies complex logistics transactions, and we are excited to partner with them for their next phase of growth.”

“Real-time visibility at the gate and in the yard is no longer an option—it is a baseline requirement for modern logistics,” said Amir Hoss, Founder and CEO of EAIGLE. “By leveraging our computer vision data, enterprises can drastically optimize gate and yard operations, reduce overhead costs, have unparalleled real-time visibility into gate & yard operations, and maintain a competitive edge in an increasingly demanding market. This funding allows us to scale these capabilities faster.”

“Knowing precisely where assets are across the supply chain is fundamental to profitability for manufacturers, transporters, and retailers alike,” added Justin Gray, Co-Founder and Managing Partner of In Revenue Capital. “EAIGLE’s ability to deploy best-in-class computer vision AI using a facility’s existing hardware completely changes the revenue equation for logistics hubs, removing the traditional friction of costly tech overhauls.”

“Every truck through a gate used to be chaos and clipboards. EAIGLE made it infrastructure. We’re proud to back a Canadian company quietly building the intelligence layer for global logistics,” stated David Charbonnea, Managing Partner Boreal Ventures.

Building on its core automation platform, EAIGLE recently launched YardSight Mobile™, expanding real-time yard visibility through advanced machine vision tailored specifically for shunting trucks.

About EAIGLE
EAIGLE is an industry-leading computer vision and data orchestration platform automating gate and yard operations. The company’s AI-native platform enables enterprise supply chain and logistics sectors to leverage existing camera infrastructure to solve complex security, transportation, and operational challenges. For more information, visit eaigle.com

About Noro-Moseley
Noro-Moseley Partners is a growth equity firm backing leading entrepreneurs in B2B software. Since 1983, NMP has invested more than $1 billion across more than 200 companies, and the managers of NMP’s current fund, Noro-Moseley Partners IX, have more than 100 years collectively of direct growth equity investing experience. Through NMP’s domain expertise, active board participation, and significant network built over decades, the firm aims to support management teams through key inflection points on their company’s growth trajectory. For more information, visit, noromoseley.com

About In Revenue Capital
In Revenue Capital was founded on the fundamental maxim that Go-to-Market excellence forms the last true moat in startups. We partner with top-tier Venture Capital firms to identify the absolute best early-growth B2B Vertical SaaS startups for co-investment. Beyond capital, we provide embedded GTM expertise in a true value-add model we call ‘Operator Immersive.’ This sleeves-up, hands-on approach enables our portfolio companies to outpace their peers and win markets, while our partners de-risk their investments. For more information, visit inrevenue.com

About Boreal Ventures
Boreal Ventures is an early-growth equity firm backing capital-efficient B2B software companies in the overlooked but essential corners of the economy — industrial tech, logistics, compliance, manufacturing and beyond. With roughly C$100M under management across two funds, Boreal partners with founders past product-market fit and gets hands-on on go-to-market to help Canadian companies scale into global markets. Learn more at boreal.vc. For more information, visit boreal.vc

Media Contact:
Dillon Screwchi
Director of Marketing
[email protected]

Media Contact
Kristin Hege
[email protected]
480.540.6496

SOURCE EAIGLE

Launch adds ordering tools for automated clinical action, a patent-pending AI specimen collection observation system, and competitive tools for independent labs

FORT WORTH, Texas, June 23, 2026 — Global Diagnostics Technologies LLC (dba Diagnostic.ly), a leader in at-home diagnostics, today announced a major platform expansion that helps healthcare organizations turn diagnostic results into automated clinical action, catch specimen collection failures in real time, and equip independent laboratories to compete and win. The new tools extend the platform from test ordering through treatment and proof of efficacy—a single, automated system for acting on diagnostic data.

At the center of the launch are new tools for ordering entities that power Test & Treat and Treat & Prove workflows. Any healthcare organization can automate the recommendations that follow a diagnostic result—closing the loop between testing and treatment—or automate the follow-up tests that prove the efficacy of recommendations such as supplements, hormones, and peptides, creating a measurable connection between what a patient is told to do and the outcomes that follow.

Diagnostic.ly also introduced its patent-pending AI specimen collection observation system. By identifying failed collections at the moment of collection rather than after a sample reaches the lab, the system cuts the cost of failed collections by up to 90 percent while improving patient satisfaction and speeding results. Failed collections have long been one of the most expensive points in at-home testing, forcing repeat shipments and delaying diagnoses—problems the new system solves at the source.

“70% of health journeys start with at-home diagnostics, but until Diagnostic.ly, the best the industry could deliver were experiences that felt like furniture assembly: patients left alone to collect a specimen from a sketchy paper instruction sheet,” said David Shor, Founder and CEO of Diagnostic.ly. “We now leverage patent-pending AI observation technology for a high-impact digital collection experience, and it’s making a major difference. When patients do make uncorrectable mistakes, automated reshipment of just the failed collection saves significant time and money for our clients.”

For its independent laboratory partners, the company unveiled tools to strengthen competitive positioning. Labs gain a clear view of where they stand against their competitive set—without identifying the specific competitor—helping them make informed decisions and close gaps. “Our tools are designed to raise all ships in the at-home labs market, not drive a race to a pricing bottom. We introduced AI-assisted road mapping, profitability analysis, and proposal generation to help our lab partners respond faster, sharpen their pitch, and win more business,” said Shor.

The new capabilities are available now to Diagnostic.ly’s partners.

About Diagnostic.ly

Global Diagnostics Technologies LLC (Diagnostic.ly), builds the infrastructure that powers modern at-home diagnostics. Its platform connects testing, treatment, and proof of efficacy so healthcare organizations and laboratories can deliver faster, smarter, and more reliable care.

Media Contact
Diagnostic.ly Media Relations
+1 310-897-2667
[email protected]

SOURCE Diagnostic.ly

Funding to accelerate commercialization of Re-Q and expand pipeline built on breakthrough science targeting the biology of skin aging

CARLSBAD, Calif., June 23, 2026 — Rapalogix Health, a biotechnology company pioneering a new category of longevity-based skin health, today announced the successful closing of a $20 million Series A financing round co-led by Woodline Partners and GordonMD Global Investments LP. The proceeds will support the rapid commercial expansion of Re-Q Health™ (Re-Q), the company’s professional skincare line, while advancing a pipeline of next-generation products designed to address the underlying biological mechanisms of skin aging.

Founded by skin longevity scientist Rahul Mehta, PhD, renowned dermatologist Doris Day, MD, and leading healthcare executive Brent Saunders, Rapalogix was created with a simple but ambitious vision: to translate advances in longevity science into products that help people maintain healthier, more resilient skin.

While most skincare products target the visible signs of aging, Rapalogix is focused on the biology that drives aging itself. The company’s scientific platform is built around TORC1, one of the most extensively studied cellular pathways associated with aging and age-related decline.

“This financing marks a significant milestone for Rapalogix and reflects the strength of the science underlying our platform,” said Dr. Mehta, CEO of Rapalogix Health. “We’re building toward a future where skin health and longevity are addressed at the cellular level, and this capital enables us to bring that vision to more patients and physicians across the country while advancing our next generation of therapeutics. Our growth strategy puts our premier dermatology physician partners at the forefront, as we collaborate directly with them to drive clinical innovation and advance longevity science in dermatology.”

Rapalogix’s lead product, Pro-Longevity Face Serum, from its professional skincare line, Re-Q, is based on the company’s proprietary approach to selectively modulating TORC1 activity in skin cells. This approach builds on Cambrian Bio’s TORnado platform, which solved a longstanding challenge in achieving selective TORC1 modulation, and Rapalogix was spun out to apply this breakthrough to skin health. By selectively supporting key cellular processes associated with skin function and resilience, the company believes it can help establish an entirely new approach to healthy skin aging.

Series A financing will support:

• Rapid expansion of commercial activities for Re-Q
• Continued investment in clinical and translational research
• Development of additional products targeting skin longevity, hair health and other age-related changes in skin biology
• Expansion of scientific, medical and commercial capabilities

“For years, dermatology has largely focused on treating the visible manifestations of aging,” commented Dr. Day. “What excites me about Rapalogix is its focus on the biology that drives skin aging. Advances in longevity science are creating opportunities to rethink how we support skin health, and we believe we’re only beginning to unlock that potential.”

“We’re still in the early innings of understanding how longevity science can transform human health. Our vision is to build the leading longevity-based skin health company and create products grounded in rigorous science that help people maintain healthier skin as they age,” commented Saunders.

The financing follows a significant period of recognition and growth for Rapalogix Health. In 2026, the company earned several industry awards and made strategic additions to its leadership team, in addition to growing its commercial salesforce in support of the Re-Q national launch. Most recently, in conjunction with this funding, Rapalogix appointed Neetu Dhaliwal and Craig Gordon, MD, to its Board of Directors, further strengthening its governance as the company enters its next phase of growth.

About Rapalogix Health
Rapalogix Health is a California-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products. Re-Q Pro-Longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at dermatology and aesthetic practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.

For more information on Rapalogix Health, visit www.rapalogix.com and follow Rapalogix on LinkedIn and Instagram.

For more information on Re-Q, visit www.reqhealth.com and follow Re-Q on Instagram.

About Cambrian Bio
Cambrian Bio (Cambrian BioPharma Inc.) is a clinical-stage drug development company focused on building therapeutics to treat and prevent today’s most debilitating chronic diseases, with programs targeting critical metabolic sensing functions that decline with age, including AMPK and mTOR. To learn more, visit www.CambrianBio.com and follow us on LinkedIn and X.

About Woodline Partners
Woodline Partners implements a fundamental equity investment strategy, represented by a tenured team of global industry specialists. Anchored by corporate partnerships, the firm’s research process aims to identify company-specific insights that drive the long-term competitiveness of companies under coverage. Woodline manages approximately $22 billion in assets across four global offices.

About GordonMD Global Investments LP
GordonMD Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with 15+ years of buy-side experience managing global biopharmaceutical portfolios. The firm manages private funds and a public fund, each focused on differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan. GordonMD’s investment approach combines first-hand medical knowledge with rigorous bottom-up analysis to identify prospective investments with the greatest growth opportunities.

SOURCE Rapalogix Health, Inc.

Funding backed by A16Z Scout, Drysdale, Motier Ventures, and industry angels accelerates development of agentic media buying, programmatic’s “killer app”

NEW YORK and PARIS, June 23, 2026 — Concord, the agentic media buying platform, today announced a $3 million seed funding round backed by A16Z Scout, Drysdale, Motier Ventures, Better Angle, and a group of industry angels including Rémi Lemonnier, co-founder of Scibids AI (acquired by DoubleVerify), Philippe Corrot (Mirakl), Arthur Querou (Vibe.co), and Thomas Zaepffel (Adot).

Concord Agent, the company’s flagship product, turns briefs into live campaigns and manages pacing and optimization against campaign KPIs across media platforms simultaneously. The company’s ambition is straightforward: to become the execution infrastructure through which major media budgets flow, enabling media buyers to grow their brands’ market share.

Concord sits natively across DV360, Meta, YouTube, Amazon DSP, The Trade Desk, TikTok, Google Ads and other major buying platforms and works with advertisers in the WPP and Havas agency footprint globally. Early users save up to 70% of the time spent on today’s manual buying loop between execution, optimization and reporting of media campaigns.

“The programmatic stack has delivered abundant media and data access plus media management tools, all of which strain the ability for human buyers to keep pace,” said Mathias Adam at A16Z Scout. “Concord’s buying agents are the “killer app” for programmatic marketing. Concord is automating the last manual processes in media buying, and doing it across every major platform simultaneously with agents that carry out complex tasks on behalf of the media buyer. This is not an incremental fix. It is the execution architecture built for the next era of media buying.”

The round draws validation from one of adtech’s most credible voices. Rémi Lemonnier, who co-founded Scibids and built it into the first customizable AI decisioning layer of programmatic before its acquisition by DoubleVerify, is backing Concord as the execution layer the industry has been missing.

“I spent ten years building the decisioning layer of programmatic with Scibids. The execution layer has yet to be built. It is the missing link of this industry, and Concord is the first team I have seen going after it with the right level of experience and ambition,” said Lemonnier.

“Media buying is still held together by manual work spread across a dozen disconnected platforms,” said Nathan Venezia, CEO and co-founder of Concord. “We are building the infrastructure it runs on. Execution should be automated, learning from past campaigns so every team can focus on strategy instead of manual, low-value operations.”

The company was co-founded by Nathan Venezia, who previously founded and sold Manadge to iHeartMedia, one of the largest media companies in the United States, alongside Nicolas Cosson (CTO) and Antoine Chwalek (Head of Engineering), who previously built and led the adtech platform at Adot (Veepee Ads).

The new funding will accelerate product development, expand platform coverage, and grow the team as Concord scales its presence across the US and EMEA.

About Concord

Concord is the agentic media buying platform. Concord Agent turns briefs into live campaigns, manages pacing and optimization across every major buying platform simultaneously, and learns from every campaign to make the next one smarter. Built as the execution infrastructure for modern media buying in the intelligence era, Concord works with large global agencies and major advertisers across the US and EMEA. For more, visit concord.ad.

SOURCE Concord

Strategic investors include EverGreen Fund – The NVIDIA Alumni Investment Network, SparkLabs Group, and other leading backers supporting the future of AI-powered space technology.

PASADENA, Calif., June 23, 2026 — Sophia Space, the company building the next generation of AI infrastructure and intelligent systems for the space economy, today announced the finalizing of a $7 million SAFE financing round, bringing the company’s total funding to $22 million to date.

The round includes participation from EverGreen – The NVIDIA Alumni Investment Network – Evergreen, SparkLabs Group, and other strategic investors who share Sophia Space’s vision of accelerating the convergence of artificial intelligence and space technologies.

The new capital will be used to expand product development, grow engineering and commercial teams, accelerate strategic partnerships, and support deployment of Sophia Space’s technology platform across government, commercial, and international markets.

“This financing marks an important milestone,”said Rob DeMillo, Founder and CEO of Sophia Space. “As initiatives like Golden Dome and proliferated satellite constellations reshape the space landscape, demand for autonomous, on-orbit computing is growing rapidly. We’re grateful for the support of investors who share our vision for the future of intelligent space infrastructure.”

The participation of EverGreen, SparkLabs, and other prominent technology-focused investors underscores growing market confidence in the transformative potential of AI-enabled space technologies and autonomous systems.

“EverGreen backs companies at the frontier of AI infrastructure, and Sophia Space is a direct expression of that mission. Building modular, AI-optimized compute for orbit isn’t an adaptation of Earth-based architecture. It’s a ground-up rethink. Our network brings deep expertise across the full AI and HPC stack, and we’ll support Sophia not just at close but through the technical and commercial milestones ahead,” said Jeff Brown, Founding Partner at EverGreen, the NVIDIA Alumni Investment Network. .  

“Sophia Space is operating at the intersection of two of the most transformative technology trends of our time: artificial intelligence and the expanding space economy,” noted Bernard Moon, Co-founder & Partner at SparkLabs Group.  “Their team has demonstrated a clear vision, strong technical execution, and a compelling strategy for building the intelligent infrastructure that future space operations will require.”

Since its founding, Sophia Space has focused on developing technologies that enable more intelligent, scalable, and autonomous operations across the rapidly expanding space economy. The company is positioned at the intersection of artificial intelligence, advanced computing, and aerospace innovation, addressing emerging opportunities in both terrestrial and orbital environments.

“We believe the future of space will be increasingly driven by intelligent systems,” added Founder and CTO Dr. Leon Alkalai. “This investment allows us to move faster, deepen our technical capabilities, and continue delivering solutions that help define the next era of space innovation.”

With total funding now reaching $22 million, Sophia Space is accelerating its roadmap while expanding its presence within the global AI and aerospace ecosystems.

About Sophia Space  

Sophia Space is building advanced AI-powered technologies and infrastructure for the emerging space economy. By combining cutting-edge artificial intelligence, autonomous systems, and aerospace innovation, the company enables organizations to operate more intelligently, efficiently, and securely across space and terrestrial environments.

SOURCE Sophia Space

TurboFlow makes sophisticated trading simple, fair, and accessible

• TurboFlow has processed $19.15B in total trading volume across 14.54k + total users
• The round is led by Pantera Capital, with participation from Susquehanna Crypto and Digital Currency Group (DCG)
• TurboFlow provides retail users with access to professional-grade market infrastructure through a transparent, high-liquidity platform that’s simple, fair, and accessible, built for the next generation of global traders

SINGAPORE, June 22, 2026 — TurboFlow, an on-chain trading ecosystem designed to bring institutional-grade market access to everyday users, today announced the closing of a $6 Million seed funding round led by Pantera Capital, with participation from Susquehanna Crypto and Digital Currency Group (DCG).

The funding will support TurboFlow’s mission to democratize access to sophisticated trading products by combining perpetual contracts and prediction markets within a single high-performance platform. Both categories are surging: according to CoinGecko Research, crypto perpetual futures volume climbed from $4.14 trillion to $7.24 trillion year-over-year by January 2026, while according to Artemis data, prediction market volumes grew nearly 4X in 2025 to $64B and are on pace to exceed $325B in 2026, with analysts projecting volumes could exceed $1.1 trillion by 2030.

The two markets are converging: perps let traders express a continuous view on an asset’s price, while prediction markets let them express a continuous view on an event’s outcome, two sides of the same underlying instinct to price uncertainty in real time. As that line between categories disappears, TurboFlow is built for exactly this shift, pairing institutional-grade infrastructure with an intuitive, consumer-focused platform that unifies both products into a single venue. The company will use the capital to expand product development, strengthen liquidity infrastructure, and accelerate global user growth.

“Our vision is simple: everyone deserves a seat at the table,” said Tony He, Founder of TurboFlow. “For too long, the best trading opportunities and infrastructure have been reserved for institutions. TurboFlow combines the simplicity consumers expect from modern apps with the liquidity, execution quality, and risk management systems traditionally available only to professional market participants. With the support of Pantera, Susquehanna Crypto, and DCG, we’re accelerating our mission to make powerful financial markets accessible to anyone, anywhere.”

TurboFlow is pioneering what it calls “high-velocity event trading” — a new approach to prediction and derivatives markets designed for speed, accessibility, and ease of use. The platform enables users to participate in markets with entry thresholds as low as $2 while benefiting from institutional-quality liquidity and pricing.

“Financial markets work best when participation is broad and access is equitable,” said Paul Veradittakit, Managing Partner at Pantera. “TurboFlow’s vision of making institutional-grade trading infrastructure available to anyone, anywhere aligns with our belief that blockchain technology can create more transparent and inclusive markets. With strong early traction and a clear product vision, we believe TurboFlow is building an important piece of the future of on-chain trading.”

Key features of the platform include:

• Fast Settlements: Optimized infrastructure designed to support short-duration event contracts and rapid capital efficiency.
• Accessible Participation: Low minimum trade sizes that reduce barriers to entry for users worldwide.
• Consumer-First Design: A streamlined trading experience that abstracts blockchain complexity while preserving transparency and self-custody principles.

TurboFlow believes the convergence of prediction markets and perpetual trading represents a significant opportunity to create more efficient, transparent, and accessible financial markets. As the platform grows, the company plans to expand partnerships across the broader digital asset ecosystem and provide developers with access to its liquidity and risk infrastructure.

“This funding represents more than capital,” added He. “It’s validation that the future of trading should be more open, more intuitive, and more accessible. We’re building the infrastructure that allows anyone—not just institutions—to participate in global markets on equal footing.”

To learn more, visit the TurboFlow website and follow them on X.

About TurboFlow
TurboFlow is an on-chain trading ecosystem at the intersection of perpetual contracts and prediction markets. Built on the belief that trading should be simple, fair, and accessible, TurboFlow provides retail users with access to professional-grade market infrastructure through a transparent, high-liquidity platform designed for the next generation of global traders.

Media Contact
[email protected]

SOURCE TurboFlow

NEW YORK, June 22, 2026 — Kudu Investment Management, LLC (Kudu), a leading provider of permanent capital solutions to asset and wealth management firms globally, and Drummond Capital Partners (Drummond), an Australian boutique manager specializing in institutional quality, active managed accounts, today announced that Kudu has made a minority investment in Drummond.

Drummond’s founders, Tom Schubert and Nick Reddaway, will remain majority owners and Drummond will continue to operate under the same leadership team, investment framework and client service model. Founded in 2017, Drummond, with offices in Melbourne, Brisbane, Sydney and Perth, manages A$6.6 billion in assets in tailored investment portfolios for financial advisors.

“We see a promising long-term opportunity in the Australian wealth management sector,” said Chris Shin, partner and co-CIO at Kudu. “Drummond is a high-quality business with a differentiated offering and coherent strategic direction. Our role is to provide long-term capital to support that vision—without altering what makes the firm successful.”

Tom Schubert, co-founder and CEO of Drummond, said, “This partnership is about strengthening what already makes Drummond different. We were very deliberate in seeking a partner whose capital is permanent, whose approach is genuinely long-term, and whose model allows us to remain fully independent. We have built a high-quality business by partnering closely with advice firms, and this investment enables us to continue investing in our team, our product suite and the broader support we provide to clients.”

About Drummond Capital Partners
Drummond is an Australian based boutique investment manager specialising in advice-led managed account solutions. Drummond partners with select advice firms to design, deliver and manage SMA portfolios that enhance investment outcomes, strengthen governance and support better client engagement. The firm was founded in 2017 with a clear objective: to bring institutional quality investment management into the wealth management sector in a way that is practical, transparent and aligned with how advice businesses operate. For more information, visit www.drummondcp.com.

About Kudu Investment Management, LLC
New York-based Kudu Investment Management provides long-term capital solutions—including generational ownership transfers, management buyouts, acquisition and growth finance, as well as liquidity for legacy partners—to independent asset and wealth managers globally. Since its founding in 2015, Kudu has invested in 34 asset and wealth managers representing US$154 billion as of March 31, 2026. Kudu is backed by capital partners White Mountains Insurance Group, Ltd. (NYSE: WTM) and MassMutual. For more information, visit www.kuduinvestment.com.

For Kudu Investment Management:

Margaret Kirch Cohen
Newton Park PR
[email protected]
+1 847-507-2229

SOURCE Kudu Investment Management, LLC

LOS ANGELES, June 22, 2026 — Global law firm Greenberg Traurig, LLP represented Apex Technologies (Apex), a manufacturer of configurable satellite bus platforms, in connection with its Series E funding round. The financing raised more than $200 million, bringing Apex’s valuation to $2.3 billion, according to its press release.

The new funds will support further vertical integration of key subsystems and fund ahead-of-need manufacturing of its satellite platforms as demand for commercial and national security constellations continues to grow. Founded in 2022, Apex is meeting the demands of a rapidly expanding space industrial base by shifting satellite manufacturing from bespoke builds to scalable infrastructure through standardized, pre-built satellite platforms.

Greenberg Traurig’s Corporate team advising Apex was led by Shareholder Daniel Wu and included Shareholder Kyle Jaep, Associate Jiwon (Jessica) Lee, and Paralegal Perky Karmire.

Lawyers in the firm’s Space & Satellite Group advise companies across an evolving space industry, leveraging a global team with deep experience in areas such as government contracts, regulatory compliance, financing, intellectual property, and dispute resolution. The team helps clients navigate complex legal, legislative, and commercial challenges in the growing space economy.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,100 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm’s broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI “Best of the Best Recommended Law Firm” by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

New funding will power foundational primary cell data generation to advance AI-driven discovery through the company’s full product launch.

MONTREAL and BOSTON, June 22, 2026 — DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuing their strong support.

This funding will drive commercialization: scaling manufacturing, building commercial operations, and accelerating customer adoption. The rollout follows successful validation through DropGenie’s Early Access Program, with many major global pharma, biotech, and research customers already integrating the technology into their workflows.

DropGenie’s platform enables high-throughput, miniaturized gene editing workflows that reduce the number of cells and reagents required per experiment — lowering costs and accelerating editing turnaround time. This enables direct edits on primary patient cells, delivering more biologically relevant insights earlier in the R&D process.

“The most powerful insights in biology come from perturbations—changing one thing and watching how a living system responds. But capturing those signals with fidelity demands working at the right scale, in the right cells,” said Alison Hirukawa, CEO & Co-founder of DropGenie. “Our platform miniaturizes workflows and lowers cell requirements to enable direct editing of primary patient cells—giving researchers access to true biological readouts previously impossible to capture. This opens the door to faster, more predictive development across cell therapy, functional genomics, and beyond.”

“We find the DropGenie platform’s ability to reliably miniaturize and accelerate experimental workflows via automation to be extremely compelling,” said Ann Lai, Managing Partner of Skeleton Key. “Being able to capture every parameter variation of these complex gene editing experimental processes creates the data we need to fundamentally accelerate innovation and to better leverage AI beyond the theoretical discovery phases. This is exactly the kind of science technology Skeleton Key wants to support and see succeed.”

The Seed+ round powers DropGenie’s strategic data partnerships with customers to generate high-quality, standardized gene editing data. As industry demand grows for data infrastructure, DropGenie’s efficient process creates foundational datasets that fuel data-driven discovery in cell therapy and functional biology—producing datasets that capture true biology at scale.

About DropGenie
DropGenie advances next-generation gene editing through miniaturized, high-efficiency workflows. Based in Montreal and Boston, DropGenie enables direct edits on primary patient cells by dramatically reducing the number of cells required per experiment, delivering true biological signals and accelerating development across cell therapy, functional genomics, and AI-driven discovery. For more information on how we’re miniaturizing gene editing workflow, please visit https://dropgenie.com/

SOURCE DropGenie